Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to...

|About: Idenix Pharmaceuticals, Inc. (IDIX)|By:, SA News Editor

Wedbush takes a shine to Idenix Pharmaceuticals (IDIX +3.5%), ringing up an upgrade to Outperform from Neutral to go along with a $5 price target hike to $11. Analysts with the firm tie the new rating to the "heightened premium" they see big-pharma placing on the nucleotide class of drugs following positive data released on Pharmasset’s (VRUS +2.3%) PSI-7977 treatment.